Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leelamine is a naturally occurring tricyclic diterpene amine, primarily derived from the bark of pine trees (*Pinus* species). It has emerged as a potent anti-cancer agent, particularly in the context of melanoma, due to its unique ability to simultaneously inhibit multiple oncogenic signaling pathways, including PI3K/Akt, MAPK/Erk, and STAT3. Its primary mechanism of action involves the disruption of lysosomal cholesterol trafficking, which leads to the sequestration of cholesterol within lysosomes and the subsequent inhibition of signaling proteins that rely on cholesterol-rich membrane domains for activation. Preclinical studies have demonstrated that leelamine can significantly reduce tumor growth and vascularization while inducing apoptosis in melanoma cells, all while maintaining a favorable safety profile in animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leelamine.